Takeda Pharmaceutical (TAK) Equity Average (2018 - 2026)

Takeda Pharmaceutical's Equity Average history runs 9 years deep, the most recent figure standing at $49.6 billion for Q1 2026.

• In Q1 2026, Equity Average rose 5.29% year-over-year to $49.6 billion; the TTM figure through Mar 2026 stood at $49.6 billion (up 5.29% YoY), while the FY2026 annual figure was $48.6 billion, up 1.26% from the prior year.
• Equity Average was $49.6 billion for Q1 2026 at Takeda Pharmaceutical, up from $49.0 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $49.7 billion in Q3 2023 to a low of $45.9 billion in Q1 2023.
• Historically, Equity Average has averaged $48.1 billion across 5 years, with a median of $47.9 billion in 2025.
• The sharpest annual moves came in 2025 and 2026: Equity Average slipped 6.32% in 2025, then climbed 5.29% in 2026.
• A 5-year view of Equity Average shows it stood at $46.2 billion in 2022, then advanced by 2.44% to $47.3 billion in 2023, then rose by 4.87% to $49.6 billion in 2024, then declined by 1.12% to $49.0 billion in 2025, then grew by 1.2% to $49.6 billion in 2026.
• The last three Equity Average figures came in at $49.6 billion (Q1 2026), $49.0 billion (Q4 2025), and $47.9 billion (Q3 2025), per Business Quant data.